Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
170.54
+2.16 (+1.28%)
4:47:31 PM EDT: $170.65 +0.11 (+0.07%)
Products

Janssen Submits Biologics License Application To U.S. FDA Seeking Approval Of Teclistamab For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Published: 12/29/2021 13:07 GMT
Johnson & Johnson (JNJ) - Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients With Relapsed Or Refractory Multiple Myeloma.
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients With Relapsed Or Refractory Multiple Myeloma.